Development of In Vitro Functional Assays From Primary Cells of Patients With Monogenic Diseases
NCT03763864 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2024-08-02
Summary
The objective of this project is to build a collection of biological samples consisting of fibroblasts and primary keratinocytes from patients with orphan monogenic diseases and to use these cells in the customization of functional tests. The miniaturized tests we are setting up make it possible to distinguish patient cells from control cells. They can be used to test molecules or for the development of diagnostic tests.
As part of the research protocol, the investigating physicians will be able to perform a skin biopsy on their patient included in the study. APTEEUS will isolate fibroblasts and keratinocytes and ensure their preservation. As part of the project, it is planned to preserve the biological samples collected and to preserve the collection after the end of the study. Skin fibroblasts and keratinocytes that are isolated from the biopsy are cells that can be preserved and amplified. They are a material of choice for the functional study of many monogenic diseases.
This study will allow the adaptation of tools dedicated to the functional study of monogenic diseases in order to help in the research and development of new treatments for these diseases, but also to highlight and explain the inter-individual variability of symptoms and responses to treatments, and finally, to help in the development of diagnostic methods.
Patients with orphan monogenic diseases whose genetic defect has been confirmed and for whom the study of the disease can be performed on fibroblasts, keratinocytes or cells derived from them, may be included in the study. Subjects, after information and consent, will undergo a skin biopsy. The sample will be sent directly to the promoter company APTEEUS, which will carry out all in vitro developments. The fibroblasts and keratinocytes will be preserved and will constitute a collection of cells "orphan monogenic diseases". The samples can be reused for new research in the same field.
Conditions
- Monogenic Disorders
Interventions
- OTHER
-
Skin Biopsy
Skin Biopsy
Sponsors & Collaborators
-
Apteeus
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-09-06
- Primary Completion
- 2025-09-06
- Completion
- 2025-09-06
Countries
- France
Study Locations
More Related Trials
-
Extension Study of PRX-102 for up to 60 Months
NCT01981720 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients
NCT06308718 ·Status: TERMINATED
-
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
NCT07185256 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201
NCT04999059 ·Status: TERMINATED
-
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
NCT03317366 ·Status: NO_LONGER_AVAILABLE
-
Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy
NCT05694598 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion
NCT05186324 ·Status: COMPLETED
-
Single Dose Pharmacokinetic (PK) Study
NCT03109756 ·Status: COMPLETED ·Phase: PHASE1
-
Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease
NCT03454893 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of RO4917523 in Patients With Fragile X Syndrome
NCT01517698 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
NCT06328608 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)
NCT03349242 ·Status: COMPLETED
-
Study of Infigratinib in Children With Achondroplasia
NCT04265651 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)
NCT06345898 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Phase 1/2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients With FOXG1 Syndrome (FS)
NCT07293546 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Ability of a Molecule (Prima) to Restore Physiological Differentiation in Epithelium Expressing Gene p63
NCT02896387 ·Status: TERMINATED
-
Fabry Disease Registry & Pregnancy Sub-registry
NCT00196742 ·Status: RECRUITING
-
A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome
NCT01750957 ·Status: COMPLETED ·Phase: PHASE2
-
Disease Progression in Women With X-linked Adrenoleukodystrophy
NCT06178120 ·Status: RECRUITING
-
A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)
NCT05543174 ·Status: COMPLETED ·Phase: PHASE3
-
A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene
NCT03605069 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders
NCT03855631 ·Status: COMPLETED
-
Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease
NCT06539624 ·Status: RECRUITING ·Phase: NA
-
MPS (RaDiCo Cohort) (RaDiCo-MPS)
NCT06036693 ·Status: RECRUITING
-
A Study of RG1662 in Individuals With Down Syndrome
NCT01436955 ·Status: COMPLETED ·Phase: PHASE1